Abstract

Diagnostic criteria for antibody-mediated rejection (AMR) were established as part of the International Society for Heart and Lung Transplantation (ISHLT) endomyocardial biopsy (EMB) grading scheme. This new scheme designates AMR as either absent (AMR 0) or present (AMR 1), without grading severity. Yet, we had previously shown that the prominence of histologic and immunofluorescence (IF) findings of AMR varies across EMBs. In this study, we hypothesized that the severity of AMR on pathology correlates with an increased risk of cardiovascular mortality (CVM) in heart transplant recipients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.